BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Wang, Mingxing; Li, Wanjun; Xing, Xuemei; Zhang, Dan; Lei, Jie; Li, Guoyin

doi:10.18632/oncotarget.20715

Cited by 11 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the current meta-analysis which summarized 11 studies involving 1041 patients showed that positive BRCA1 expression was associated with a shorter OS and DFS without regional disparities. The conclusion was consistent with the results of the previous studies[ 18 , 21 , 25 , 26 ]. BRCA1 expression status could serve as a novel indicator for the assessment of prognosis and formulation of therapy strategy for resected NSCLC patients.…”

Section: Discussionsupporting

confidence: 93%

Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

Gao¹,

Luo²,

Yang³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND The clinical significance of breast cancer susceptibility gene 1 (BRCA1) in non-small cell lung cancer (NSCLC) patients undergoing surgery remains unclear up to now. AIM To explore the relation of BRCA1 expression with clinicopathological characteristics and survival in patients with resected NSCLC. METHODS EMBASE, PubMed, Web of Science, and The Cochrane Library databases were searched to identify the relevant articles. To assess the correlation between the expression of BRCA1 and clinicopathological characteristics and prognosis of patients with resected NSCLC patients, the combined relative risks or hazard ratios (HRs) with their corresponding 95% confidence intervals [CIs] were estimated. RESULTS Totally, 11 articles involving 1041 patients were included in the meta-analysis. The results indicated that the expression of BRCA1 was significantly correlated with prognosis of resected NSCLC. Positive BRCA1 expression signified a shorter overall survival (HR = 1.60, 95%CI: 1.25-2.05; P < 0.001) and disease-free survival (HR = 1.78, 95%CI: 1.42-2.23; P < 0.001). However, no significant association of BRCA1 expression with any clinicopathological parameters was observed. CONCLUSION BRCA1 expression indicates a poor prognosis in resected NSCLC patients. BRCA1 might serve as an independent biomarker to predict clinical outcomes and help to customize optimal adjuvant chemotherapy for NSCLC patients who had received surgical therapy.

show abstract

Section: Discussionsupporting

confidence: 93%

Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

Gao¹,

Luo²,

Yang³

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…Subgroup analysis on the detection method and tumor stage IIIb–IV showed no significant decrease in the heterogeneity. The OS of resectable 16,22,23,30 and inoperable 20,24–26 NSCLC patients after platinum-based chemotherapy was clearly reported in four studies. For OS, there was no significant decrease in heterogeneity in subgroup analyses of both operable and inoperable NSCLC patients treated with platinum-based chemotherapy.…”

Section: Resultsmentioning

confidence: 97%

BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II–IV non-small cell lung cancer: A meta-analysis

Huang

Xiong

2022

Int J Biol Markers

View full text Add to dashboard Cite

Purpose To explore the relationship between breast cancer susceptibility gene 1 (BRCA1) expression and the prognostic value of platinum-based chemotherapy for stage II–IV non-small cell lung cancer (NSCLC). Methods PubMed, Web of Science, Embase, and Cochrane Library were searched from inception to August 2021, for retrieving literature related to BRCA1 expression and prognostic value of platinum-based chemotherapy in NSCLC patients. Stata 15.0 was employed for statistical analysis. Results A total of 15 articles were included. Compared with the low BRCA1 expression, its high expression negatively affected the overall survival of NSCLC patients treated with platinum-based chemotherapy (hazard ratio (HR) = 1.53, 95% confidence interval (CI): 1.01–2.31, P < 0.05). No significant difference was identified in the effect of both low and high BRCA1 expression on event-free survival (HR = 1.73, 95% CI: 0.98–3.05, P > 0.05). Subgroup analysis showed that significant differences existed in overall survival and event-free survival in Caucasian population; that is, compared with low BRCA1 expression, its high expression negatively affected the overall survival (HR = 1.79, 95% CI: 1.15–2.79, P < 0.05) and event-free survival (HR = 2.39, 95% CI: 1.43–3.97, P < 0.05). Nevertheless, there were no significant differences in overall survival and event-free survival in China. Conclusion BRCA1 expression is correlated with the prognostic value of platinum-based chemotherapy for stage II–IV NSCLC patients. In Caucasian population, compared with low BRCA1 expression, its high expression has a negative effect on the overall survival and event-free survival in stage II–IV NSCLC patients after platinum-based chemotherapy; however, this correlation was not found in China.

show abstract

“…We thus showed that STMN1 levels were adversely associated with the clinical prognosis of AML patients. STMN1 has been found to be a potential prognostic marker for patients with different types of tumors, including colon cancer (Zhang et al, 2016), gastric cancer (Bai et al, 2017), pancreatic ductal adenocarcinoma (Li et al, 2015), meningioma (Wang et al, 2017a), gallbladder carcinoma (Bo et al, 2017), osteosarcoma (Zhao et al, 2018), esophageal squamous cell carcinoma (Ni et al, 2017), (Hsieh et al, 2010) and non-small cell lung cancer (Nie et al, 2015;Wang et al, 2017b). Our data and previous reports indicated that STMN1 may not be only a prognostic marker for solid cancer but could also serve as a prognostic marker for patients with leukemia.…”

Section: Discussionmentioning

confidence: 99%

STMN1 promotes the proliferation and inhibits the apoptosis of acute myeloid leukemiacells by activating the PI3K/Akt pathway

Yang¹,

Zou²,

Gao³

2022

Biocell

View full text Add to dashboard Cite

Recent studies have shown that the microtubule disrupting protein Stathmin 1 (STMN1) is differentially expressed in AML patients and healthy control. The aim of this study was to explore the effects and molecular mechanism of STMN1 in AML. Here, the expression of STMN1 in peripheral blood cells (PBMCs) and bone marrow of AML patients and healthy volunteers was detected by RT-PCR and Western blot. STMN1 expression was regulated by transfected with STMN1 overexpressed plasmid or shRNA in two human leukemia cell lines K562 and HL60. Cell proliferation was examined by CCK8 and Edu staining. Annexin V and TUNEL assays were applied to test cell apoptosis. Flow cytometry was used to test the cell cycle distribution. The activation of the PI3K signaling pathway and the expression levels of cell cycle and cell apoptosis-related protein were determined by Western blot. In this study, we found that STMN1 was overexpressed in PBMCs and bone marrow of AML patients. STMN1 expression was closely related to FAB subtypes, risk stratification, disease-free survival, and overall survival of AML. Functional assays showed that overexpression of STMN1 in HL60 and K562 cells enhanced cell proliferation, decreased cell apoptosis, and caused G 1 phase arrest. In contrast, suppression of STMN1reduced cell proliferation and enhanced cell apoptosis in both HL60 and K562 cells. Moreover, the PI3K/Akt pathway was activated by STMN1, while suppression of STMN1 dysregulated the PI3K/Akt pathway and upregulating the levels of caspases3 and Bax expression. In conclusion, STMN1 was confirmed to promote the proliferation and inhibit the apoptosis of HL60 and K562 cells by modulating the PI3K/Akt pathway. STMN1 might be a novel molecular target for treating AML.

show abstract

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Cited by 11 publications

References 27 publications

Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II–IV non-small cell lung cancer: A meta-analysis

STMN1 promotes the proliferation and inhibits the apoptosis of acute myeloid leukemiacells by activating the PI3K/Akt pathway

Contact Info

Product

Resources

About